What is the main business of Modern Medicine?

The main business activity of Modern Medicine focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on December 16, 2020.

Where is the headquarters located?

The headquarters is located at: ul. Ludwika Waryńskiego 4, 15-461 Białystok.

Who is on the management board?

The management board consists of: Bartosz Cukierman (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

How much revenue was generated?

In 2025, the company generated total revenue of $1, representing an increase of 1188.5% compared to 2024.

No, in 2025 the company was not profitable, reporting a net loss of $2,661. For comparison, in 2024 the loss was $2,715, meaning the company reduced its loss by 2.2%.

What is the main operating cost?

The largest operating cost category falls under other operating costs. This category amounted to $2,079 in 2025, representing 100% of all operating expenses.

Modern Medicinesp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2020-12-16

Share capital

5 000,00 PLN

Registered address

ul. Ludwika Waryńskiego 4/13, 15-461 Białystok, Poland

Electronic delivery address

AE:PL-57982-72229-JADHH-26

Financials

Revenue history

Filing timeliness

3 of 6 financial statements were filed late (the longest delay 370 days for 2024).

202513/07/2026
202420/07/2026
202301/07/2024
202217/07/2023
202112/10/2022
202016/07/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 0.84MedianUSD 55.35kAverageUSD 2.71m

Net profit

This companyUSD -2.66kMedianUSD -1.27kAverageUSD -92.09k

Operating costs

This companyUSD 2.08kMedianUSD 66.19kAverageUSD 2.67m

Assets

This companyUSD 5.08kMedianUSD 133.95kAverageUSD 3.03m

Industry

Authorized Representatives

Bartosz Cukierman – President of the Management Board

Manner of representation

If there is a one-person management board – the member of the management board independently; if the management board consists of two or more members – joint action by two members of the management board or one member of the management board jointly with a commercial proxy.

Ownership

Owner	Shares	Share value	Stake
Bartosz Cukiermanage 41	90	$1,215.56	90%
Patrycja Ewa Tołłoczko Cukiermanage 41	10	$135.06	10%

Bartosz Cukierman and Patrycja Ewa Tołłoczko Cukierman hold a combined 100% – the ownership structure indicates family control.

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2020-12-16.

Erste Bank Polska
67 1090 2590 0000 0001 4735 8572

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
InventroS.A.	$12,176.61	inventro.co
Plan Biosp. z o.o.	$3,404.49	biotrem.pl
Dairy Biotechnologiessp. z o.o.	$1,485.09	milcu.eu
Medical Algorithmssp. z o.o.	$682.08	medicalalgorithms.eu
Centrum Transferu Technologii Meditransfer Iitdsp. z o.o.	$228.56	iitd.pan.wroc.pl
Fungotechsp. z o.o.	$187.68	fungo.tech
Wavex Energysp. z o.o.	$142.33	wavexenergy.com
Ncage TherapeuticsS.A.	$29.14	ncage.org
Innervisionsp. z o.o.	$4.54	innervision.pl
ImmunotronicsP.S.A.	$0.16	immunotronics.net